Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPI plus lafutidine vs PPI alone for nocturnal GERD symptoms and esophageal acid exposure
ChiCTR2200055479Phase 4Recruiting
- Sponsor
- Union Hospital of Huazhong University of Science and Technology
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lafutidine in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Union Hospital of Huazhong University of Science and Technology. Primary endpoints: 24h esophageal acid exposure time and Nocturnal acid breakthrough. Started Jan 2022; status: recruiting.
02
Drugs
lafutidine
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR2200055479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055479.